Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yu Gan Long capsule plus entecavir for liver fibrosis in chronic hepatitis B
ChiCTR-IPR-16010010Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2016
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of yuganlong and entecavir in Chronic Hepatitis B (CHB) and hepatic fibrosis, sponsored by Tongji Hospital. Primary endpoints: Fibrosis markers, Liver function tests and 2 more. Started Jul 2016; status: recruiting.
02
Drugs
yuganlongentecavir
03
Conditions
Chronic Hepatitis B (CHB)hepatic fibrosis
Beyond the preview
Go deeper on ChiCTR-IPR-16010010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16010010.